Respiratory Infections Management

Mucolytics and Decongestants

• Mucolytics, such as N-acetylcysteine, and decongestants, such as oral pseudoephedrine and topical oxymetazoline, should be used with caution in respiratory conditions, as evidence supports limited use of decongestants and caution with mucolytics, according to the American Academy of Otolaryngology-Head and Neck Surgery 1
• Guaifenesin has limited evidence for clinical efficacy in acute viral respiratory infections and is not recommended for acute bacterial rhinosinusitis due to questionable efficacy, as stated by the American Academy of Otolaryngology-Head and Neck Surgery 1
• Oral decongestants, such as pseudoephedrine, may provide symptomatic relief for nasal congestion, but should be used with caution in patients with hypertension or anxiety 1
• Topical decongestants, such as oxymetazoline, provide palliative relief of nasal congestion, but duration of use should not exceed 3-5 days to avoid rebound congestion (rhinitis medicamentosa) 1
• Antihistamines have questionable efficacy in non-allergic rhinosinusitis, and nasal purulence alone does not indicate bacterial infection and is not an indication for antibiotics 1
• Limited evidence for clinical efficacy in acute bacterial rhinosinusitis supports the use of symptomatic relief measures, including mucolytics and decongestants, as recommended by the American Academy of Otolaryngology-Head and Neck Surgery 1, 2

Nasal Saline Irrigation

• Nasal saline irrigation is recommended for symptomatic relief in both viral and bacterial rhinosinusitis, with a low risk of adverse reactions and a cleansing effect, as stated by the American Academy of Otolaryngology-Head and Neck Surgery 1
• Nasal saline irrigation is recommended for symptomatic relief in acute bacterial rhinosinusitis, with a modest increase in symptom relief (number needed to treat of 14) 1

Corticosteroids and Bronchodilators

• The American College of Chest Physicians recommends short-acting β-agonists for bronchospasm and dyspnea relief in patients with chronic bronchitis, and suggests ipratropium bromide to improve cough in these patients 3
• The American College of Chest Physicians recommends short-acting β-agonists or anticholinergic bronchodilators for acute exacerbations of chronic bronchitis, and suggests a short course of systemic corticosteroids may be beneficial for acute exacerbations of chronic bronchitis 3
• Corticosteroids, such as mometasone, fluticasone, flunisolide, and budesonide, can be used for symptomatic relief in rhinosinusitis, as recommended by the American Academy of Otolaryngology-Head and Neck Surgery 1

Mucolytic Agents

• Mucolytic agents, such as N-acetylcysteine (NAC), can reduce exacerbation rates by approximately 25% in COPD patients with frequent exacerbations, supported by the European Respiratory Society 4, 5
• NAC is generally well-tolerated, with no significant increase in adverse events compared to placebo, and rare patients may experience adverse GI effects, according to the European Respiratory Society 4, 5
• The European Respiratory Society recommends NAC at a dosage of 600 mg twice daily for patients with moderate to severe COPD who have a history of two or more exacerbations in the previous 2 years, with a Grade 2B recommendation 4
• Response to mucolytic treatment should be evaluated after 6 months, and treatment should be discontinued if there is no clinical benefit, supported by the European Respiratory Society 4, 5

Saline Nebulizers

• Tolerance to hypertonic saline should be tested before routine use, and pre-treatment with bronchodilators may be necessary to prevent bronchospasm, and patients should be monitored for gastrointestinal side effects and exacerbation frequency after 3-6 months of therapy 7, 9, 4
• Different nebulized medications should not be mixed unless safety and efficacy data are available for that specific combination, and both treatments should be regularly reassessed for clinical benefit to avoid overuse without benefit assessment 7
• Proper cleaning of nebulizer equipment is essential to prevent contamination and neglecting equipment maintenance, and airway hyperreactivity should always be considered, especially with hypertonic saline, to avoid ignoring bronchospasm risk 7, 9

Cough Suppressants

• Central cough suppressants, such as codeine and dextromethorphan, have limited efficacy for URI-related cough, with a Grade D recommendation against their use, as stated by the American College of Chest Physicians 10
• The European Respiratory Society does not recommend the regular use of oral mucolytics, including Ambroxol, in patients with chronic bronchitis and COPD for the prevention of lower respiratory tract infections, and also does not recommend their use in patients with bronchiectasis as a prevention against lower respiratory tract infections 11